# A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

> **NCT05637255** · PHASE2 · COMPLETED · sponsor: **Sylentis, S.A.** · enrollment: 99 (actual)

## Conditions studied

- Wet Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Macular Degeneration

## Interventions

- **DRUG:** SYL1801

## Key facts

- **NCT ID:** NCT05637255
- **Lead sponsor:** Sylentis, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-22
- **Primary completion:** 2024-12-19
- **Final completion:** 2024-12-19
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05637255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05637255, "A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05637255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*